The estimated Net Worth of Jeff Castelli is at least $4.45 Million dollars as of 28 December 2023. Jeff Castelli owns over 17,421 units of Amicus Therapeutics Inc stock worth over $3,839,249 and over the last 11 years Jeff sold FOLD stock worth over $611,084.
Jeff has made over 10 trades of the Amicus Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Jeff sold 17,421 units of FOLD stock worth $252,953 on 28 December 2023.
The largest trade Jeff's ever made was selling 19,154 units of Amicus Therapeutics Inc stock on 18 December 2023 worth over $253,599. On average, Jeff trades about 5,053 units every 141 days since 2013. As of 28 December 2023 Jeff still owns at least 340,661 units of Amicus Therapeutics Inc stock.
You can see the complete history of Jeff Castelli stock trades at the bottom of the page.
Jeff's mailing address filed with the SEC is 47 HULFISH STREET, , PRINCETON, NJ, 08542.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris, and Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: